Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Other Financing Activities
Financing cash flows not reported separately.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026
Other financing activities turns positive
Q3 FY2026 other financing activities was $993.7M, compared with -$3.81M a year earlier. Trailing-twelve-month other financing activities was $878.6M. Over 3 fiscal years it compounded at +18.3% a year.
Context
- Other financing activities amounted to 1.8% of revenue in FY2025, up 0.2 pp from a year earlier.
- Other financing activities grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $993.7M or moves back toward the trailing-twelve-month quarterly average of $219.65M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (75.22M) USD
- Year-over-year change
- -18.5%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (75.22M) | -18.5% |
| FY2024 | 2024-12-31 | (63.47M) | -24.6% |
| FY2023 | 2023-12-31 | (50.95M) | -12.1% |
| FY2022 | 2022-12-31 | (45.44M) | -27.6% |
| FY2021 | 2021-12-31 | (35.6M) | — |
Other Financing Activities vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 other financing activities of $878.6M is the 2nd largest of the 9 companies compared; the peer median is $16.44M.
- Its year-over-year change of +1237.7% is the 2nd highest of 7, against a peer median of -122.2%.
- Other financing activities amounts to 18.6% of revenue for JAZZ, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.21B | — | — | 126.1% | |
| LTM Sep 2026 | $878.6M | +1237.7% | +18.3% | 18.6% | |
| LTM Sep 2026 | $140.1M | — | — | 3.8% | |
| LTM Mar 2026 | $139.12M | +52398.9% | +394.4% | 88.6% | |
| LTM Jun 2026 | $96.83M | +49.3% | +18.0% | 1.7% | |
| LTM Sep 2026 | $47.61M | -1425.4% | — | 3.5% | |
| LTM Jun 2026 | $29.65M | -160.7% | -19.0% | 10.2% | |
| LTM Jun 2026 | $3.23M | -144.5% | — | 0.3% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding JAZZ) | $16.44M | -122.2% | +18.0% | 3.6% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (329.67M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| Deferred Income Tax | 69.2M | (292.25M) | (260.22M) | (208.33M) | (444.97M) |
| Stock-Based Compensation | 189.01M | 222M | 226.84M | 248.05M | 291.13M |
| Change in Working Capital | (47.95M) | 9.91M | (204.44M) | (76.72M) | 18.9M |
| Accounts Receivables | (92.74M) | (90.14M) | (51.88M) | (21.12M) | (106.28M) |
| Inventory | (48.86M) | (49.64M) | (13.42M) | (45.54M) | (86.04M) |
| Accounts Payables | 57.02M | (11.23M) | 9.6M | (20.07M) | 39.85M |
| Other Working Capital | 36.62M | 160.91M | (148.74M) | 10.01M | 171.37M |
| Other Non-Cash Items | 345.44M | 926.92M | 276.29M | 212.72M | 1.15B |
| Operating Cash Flow | 778.51M | 1.27B | 1.09B | 1.4B | 1.36B |
| Capital Expenditures | (45.53M) | (498.19M) | (23.96M) | (48.07M) | (209.75M) |
| Acquisitions (Net) | (6.23B) | 53M | 0 | 0 | (858.05M) |
| Purchases of Investments | (26.82M) | (61.04M) | (390.1M) | (1.31B) | (1.83B) |
| Sales of Investments | 1.1B | 60M | 270M | 845M | 1.36B |
| Other Investing Activities | (17.89M) | 0 | (19M) | (10M) | (122.83M) |
| Investing Cash Flow | (5.21B) | (446.23M) | (163.06M) | (508.2M) | (1.51B) |
| Debt Repayment | 3.87B | (582.01M) | (31M) | 374.77M | (781M) |
| Common Stock Issued | 135.26M | 0 | 46.46M | 20.65M | 107.86M |
| Common Stock Repurchased | 0 | (54K) | (269.76M) | (311.43M) | (125.02M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35.6M) | (45.44M) | (50.95M) | (63.47M) | (75.22M) |
| Financing Cash Flow | 3.97B | (529.49M) | (305.25M) | 20.52M | (873.38M) |
| Effect of Forex Changes | (3.21M) | (6.22M) | 1.14M | (1.68M) | 6.56M |
| Net Change in Cash | (466.32M) | 290.03M | 624.83M | 906.55M | (1.02B) |
| Free Cash Flow | 732.98M | 773.78M | 1.07B | 1.35B | 1.15B |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.